Are Analysts Bullish Chiasma, Inc. (NASDAQ:CHMA) After Last Week?

March 14, 2018 - By Stephen Andrade

 Are Analysts Bullish Chiasma, Inc. (NASDAQ:CHMA) After Last Week?

Chiasma, Inc. (NASDAQ:CHMA) Ratings Coverage

Among 3 analysts covering Chiasma (NASDAQ:CHMA), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Chiasma had 6 analyst reports since August 10, 2015 according to SRatingsIntel. The rating was initiated by William Blair on Monday, August 10 with “Outperform”. William Blair downgraded the stock to “Market Perform” rating in Monday, April 18 report. The firm earned “Underweight” rating on Tuesday, January 17 by Barclays Capital. The firm has “Overweight” rating by Barclays Capital given on Monday, August 10. The company was initiated on Monday, August 10 by Cowen & Co. Barclays Capital downgraded Chiasma, Inc. (NASDAQ:CHMA) on Monday, April 25 to “Equal-Weight” rating. Below is a list of Chiasma, Inc. (NASDAQ:CHMA) latest ratings and price target changes.

The stock decreased 1.59% or $0.03 during the last trading session, reaching $1.55. About 12,347 shares traded. Chiasma, Inc. (NASDAQ:CHMA) has declined 48.76% since March 14, 2017 and is downtrending. It has underperformed by 65.46% the S&P500.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform. The company has market cap of $37.79 million. The firm offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the bodyÂ’s production of excess growth hormone under the MYCAPSSA name. It currently has negative earnings.

More notable recent Chiasma, Inc. (NASDAQ:CHMA) news were published by: which released: “Chiasma Provides Update Regarding FDA’s Complete Response Letter for Mycapssa …” on April 18, 2016, also with their article: “Chiasma, Inc. (CHMA) Announces Agreement with FDA Under SPA for New Phase 3 …” published on August 10, 2017, published: “Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update …” on June 14, 2016. More interesting news about Chiasma, Inc. (NASDAQ:CHMA) were released by: and their article: “Chiasma Inc. CHMA (US: Nasdaq)” published on July 10, 2015 as well as‘s news article titled: “Chiasma Honors Patients, Researchers for Rare Disease Day 2018” with publication date: February 28, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: